CPC
CADL icon

Cookson Peirce & Co’s Candel Therapeutics CADL Stock Holding History

Cookson Peirce & Co’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$618K Buy
+60,000
New +$453K 0.02% 237

Other funds holding CADL

TWM
Tanager Wealth Management Goring On Thames, United Kingdom $1.15B AUM 19.91% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
CIA
Cape Investment Advisory Mcdonough, Georgia $374M AUM 21.53% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Cookson Peirce & Co's CADL Position: Q2 2026 in Review

Cookson Peirce & Co opened a new position in Candel Therapeutics (CADL) in Q2 2026: 60,000 shares worth $618K. The stake represents 0.02% of the portfolio and ranks #237 among its holdings.

12 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Cookson Peirce & Co held 60,000 shares of Candel Therapeutics worth $618K as of Q2 2026.
  • Candel Therapeutics was a new Cookson Peirce & Co position in Q2 2026.
  • Candel Therapeutics made up 0.02% of Cookson Peirce & Co's portfolio in Q2 2026, its #237 holding.
  • 12 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Cookson Peirce & Co's 13F filing for Q2 2026, filed 23 Jul 2026.